Almirall has entered into a long-term development, technology license and supply agreement with Symatese, an innovator of medical devices with more than 30 years of experience in the Aesthetic market
• The development of a new range of Hyaluronic Acid facial fillers will be the first step of this collaboration
• This agreement reinforces Almirall’s strategy to continue building a presence in Aesthetic Medicine
Almirall S.A., a global pharmaceutical company based in Barcelona, and Symatese, a leading developer and manufacturer of innovative medical devices with more than 30 years of experience, announced today that they have entered into a global collaboration for the development and commercialization of customized products in the Aesthetics field.
In accordance with the terms of this collaboration, Symatese grants Almirall an exclusive license for the commercialization of a new range of Hyaluronic Acid facial fillers worldwide in exchange of an upfront payment of €7.5 Million and subsequent event milestones, royalties and sales milestones. In line with Almirall’s strategy to continue building a presence in the Aesthetic market, this collaboration represents not only an attractive opportunity to enter the injectable facial filler market with a differentiated technology, but also create a long-term partnership with a leading developer of medical devices for aesthetic applications.
Activities will first be focused on the development of a new Hyaluronic Acid-based transformation technology. This technology will enable Almirall to provide a new, safe, efficacious and versatile range of dermal facial fillers that will satisfy patient desires to replace lost facial volume with predictable, natural looking and satisfying results.
Eduardo Sanchiz, CEO of Almirall, commented: “Following the acquisition of ThermiGen, a leading player in the radiofrequency energy-device market, with this collaboration Almirall continues to make progress with its strategic direction into Dermatology and medical Aesthetics. This long-term partnership with Symatese, a leading developer of medical devices, ensures that Almirall will have access to future innovations for the dermal filler market covering our customers unmet needs.“
Dermal filler market
The dermal filler market has demonstrated significant growth over the last decade and is expected to reach €2.4 bn in 2022 worldwide. A hyaluronic acid-based filler acts like an inflated cushion to support facial structures and tissues that may have lost volume or elasticity due to the normal aging process. It also brings hydration to the skin to keep it looking fresh and supple. Hyaluronic Acid fillers represent approximately 90% of this market. A Hyaluronic Acid filler range is considered an important base of an aesthetic portfolio, commercially synergistic with other aesthetics products.
